Dear editor, We think that this study is very important, because it is the first reported experience of aflibercept for myopic CNV in Europe, and the findings are largely consistent with those observed in the MYRROR study on Asiatic patients.
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This study was done to assess the use of intravitreal aflibercept for the treatment of subfoveal myopic choroidal neovascularization. We prospectively enrolled 33 eyes of 32 patients with a mean follow-up of 1 year. The results were very impressive with an improvement of BCVA from 0.59 ± 0.37 logMAR to 0.38 ± 0.33 logMAR at 12 months and a median number of aflibercept injections of 2.0. Increase in BCVA was greater in younger patients (aged <50 years) and those with baseline BCVA ≤75 letters.
Intravitreal aflibercept in a PRN regimen appears to be very effective in the treatment of myopic CNV with an improvement in VA very similar to that reported by other studies of anti-VEGF treatments for myopic CNV, with a very low number of injections and no short-term safety effects.
